Natixis Advisors LLC Reduces Position in Myriad Genetics, Inc. (NASDAQ:MYGN)

Natixis Advisors LLC decreased its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 34.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209,328 shares of the company's stock after selling 110,685 shares during the period. Natixis Advisors LLC owned about 0.23% of Myriad Genetics worth $2,870,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Nordea Investment Management AB grew its position in Myriad Genetics by 117.0% in the 4th quarter. Nordea Investment Management AB now owns 332,913 shares of the company's stock valued at $4,548,000 after acquiring an additional 179,527 shares in the last quarter. Jennison Associates LLC lifted its position in Myriad Genetics by 144.2% during the 4th quarter. Jennison Associates LLC now owns 59,015 shares of the company's stock worth $809,000 after acquiring an additional 34,853 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Myriad Genetics by 6.4% in the fourth quarter. Victory Capital Management Inc. now owns 61,341 shares of the company's stock valued at $841,000 after acquiring an additional 3,711 shares in the last quarter. Barclays PLC increased its holdings in shares of Myriad Genetics by 136.9% in the 3rd quarter. Barclays PLC now owns 190,243 shares of the company's stock valued at $5,210,000 after purchasing an additional 109,931 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its stake in Myriad Genetics by 26.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,063,711 shares of the company's stock valued at $29,135,000 after purchasing an additional 224,255 shares in the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Myriad Genetics Stock Performance

Shares of MYGN traded down $0.19 during midday trading on Tuesday, reaching $9.79. 238,408 shares of the stock were exchanged, compared to its average volume of 852,185. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The company has a market cap of $893.64 million, a P/E ratio of -7.53 and a beta of 1.79. The stock's 50 day simple moving average is $12.05 and its 200 day simple moving average is $16.92. Myriad Genetics, Inc. has a twelve month low of $9.36 and a twelve month high of $29.30.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The business had revenue of $210.60 million for the quarter, compared to analyst estimates of $210.35 million. During the same quarter last year, the firm posted ($0.12) EPS. On average, sell-side analysts expect that Myriad Genetics, Inc. will post -0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MYGN. UBS Group reduced their price objective on Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 25th. Leerink Partnrs lowered Myriad Genetics from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 9th. StockNews.com downgraded Myriad Genetics from a "buy" rating to a "hold" rating in a report on Thursday, March 13th. Bank of America decreased their target price on shares of Myriad Genetics from $13.00 to $11.00 and set an "underperform" rating for the company in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group cut their price target on shares of Myriad Genetics from $29.00 to $18.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Myriad Genetics presently has a consensus rating of "Hold" and a consensus target price of $21.89.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.